← All trials
NCT06128954
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 2, 2024
- Primary completion
- Jan 28, 2024
- Completion date
- Mar 29, 2024
- First posted
- Nov 13, 2023
- Last posted
- Nov 29, 2023
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ORPHALANLead sponsor
- Richmond PharmacologyOverall official - principal investigator
- Richmond PharmacologyOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.